Literature DB >> 12870166

Insulin secretion after short- and long-term low-grade free fatty acid infusion in men with increased risk of developing type 2 diabetes.

Heidi Storgaard1, Christine B Jensen, Allan A Vaag, Aage Vølund, Sten Madsbad.   

Abstract

We studied the effect of a low-grade short- and long-term 20% Intralipid infusion (0.4 mL(-1) x kg(-1) x h(-1)) on insulin secretion and insulin action in 15 elderly obese men; 7 glucose intolerant first-degree relatives of type 2 diabetic patients (impaired glucose tolerance [IGT] relatives) and 8 healthy controls of similar age and body mass index (BMI). Intravenous glucose tolerance test (IVGTT) and a graded glucose infusion (dose-response test [DORE]) were performed to determine first phase insulin response and to explore the dose response relationship between glucose concentration and insulin secretion rates (ISR). ISR were calculated by deconvolution of plasma C-peptide concentrations. Insulin action was determined by performing a 120-minute hyperinsulinemic euglycemic clamp. All tests were performed 3 times, preceded by 0, 2, or 24 hours Intralipid infusion. Disposition indices (DI) were calculated for the IVGTT. Insulin action was reduced 25% after 2 and 24 hours Intralipid infusion in both groups. In IGT relatives, the beta-cell responsiveness to glucose (measured during DORE) decreased after 2 and 24 hours Intralipid infusion (P=.02), whereas first phase insulin response (measured during IVGTT) decreased after 24 hours Intralipid infusion. Insulin secretion measured during DORE and IVGTT was not affected by Intralipid infusion in controls. DI decreased after 2 and 24 hours Intralipid infusion in the total study population. In conclusion, insulin resistance induced by low-grade short- and long-term Intralipid infusion is not balanced by an adequate compensatory increase in insulin secretion in IGT relatives or in matched controls. IGT relatives appear to be more sensitive to the deleterious effects of low-grade fat infusion on insulin secretion than normal glucose tolerant control subjects.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12870166     DOI: 10.1016/s0026-0495(03)00102-1

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  11 in total

Review 1.  Current status of the E23K Kir6.2 polymorphism: implications for type-2 diabetes.

Authors:  Michael J Riedel; Diana C Steckley; Peter E Light
Journal:  Hum Genet       Date:  2004-11-23       Impact factor: 4.132

Review 2.  Free fatty acids and insulin secretion in humans.

Authors:  Guenther Boden
Journal:  Curr Diab Rep       Date:  2005-06       Impact factor: 4.810

3.  Vascular effects of intravenous intralipid and dextrose infusions in obese subjects.

Authors:  Aidar R Gosmanov; Dawn D Smiley; Limin Peng; Joselita Siquiera; Gonzalo Robalino; Christopher Newton; Guillermo E Umpierrez
Journal:  Metabolism       Date:  2012-04-05       Impact factor: 8.694

Review 4.  Lessons learned from studying families genetically predisposed to type 2 diabetes mellitus.

Authors:  Kenneth Cusi
Journal:  Curr Diab Rep       Date:  2009-06       Impact factor: 4.810

5.  Effects of prolonged fasting and sustained lipolysis on insulin secretion and insulin sensitivity in normal subjects.

Authors:  B Salgin; M L Marcovecchio; S M Humphreys; N Hill; L J Chassin; D J Lunn; R Hovorka; D B Dunger
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-12-23       Impact factor: 4.310

Review 6.  The mechanisms linking adiposopathy to type 2 diabetes.

Authors:  Jichun Yang; Jihong Kang; Youfei Guan
Journal:  Front Med       Date:  2013-10-01       Impact factor: 4.592

7.  Impaired plasma nonesterified fatty acid tolerance is an early defect in the natural history of type 2 diabetes.

Authors:  P Brassard; F Frisch; F Lavoie; D Cyr; A Bourbonnais; S C Cunnane; B W Patterson; R Drouin; J-P Baillargeon; A C Carpentier
Journal:  J Clin Endocrinol Metab       Date:  2008-01-08       Impact factor: 5.958

Review 8.  Recent Insights Into Mechanisms of β-Cell Lipo- and Glucolipotoxicity in Type 2 Diabetes.

Authors:  Maria Lytrivi; Anne-Laure Castell; Vincent Poitout; Miriam Cnop
Journal:  J Mol Biol       Date:  2019-10-16       Impact factor: 5.469

9.  Phenotypic Screening for Small Molecules that Protect β-Cells from Glucolipotoxicity.

Authors:  Jonnell C Small; Aidan Joblin-Mills; Kaycee Carbone; Maria Kost-Alimova; Kumiko Ayukawa; Carol Khodier; Vlado Dancik; Paul A Clemons; Andrew B Munkacsi; Bridget K Wagner
Journal:  ACS Chem Biol       Date:  2022-04-19       Impact factor: 4.634

10.  Quantification of intrapancreatic fat in type 2 diabetes by MRI.

Authors:  Ahmad Al-Mrabeh; Kieren G Hollingsworth; Sarah Steven; Dina Tiniakos; Roy Taylor
Journal:  PLoS One       Date:  2017-04-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.